Sort by
Keyphrases
ABCB1 Polymorphism
13%
Age-appropriate Dosage Form
13%
Association Analysis
16%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
8%
Chemotherapy Toxicity
13%
Clear-cell Metastatic Renal Cell Carcinoma
13%
Clinical Benefit
8%
Clinical Outcomes
15%
Clinical Practice
7%
Collaborative Projects
13%
Confidence Interval
14%
CYP3A5
8%
CYP3A5 Polymorphism
13%
Cytochrome P450 3A4 (CYP3A4)
15%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
13%
Down Syndrome Cell Adhesion Molecule (DSCAM)
13%
Efficacy Outcomes
13%
Genetic Polymorphism
28%
Genetic Variants
19%
Genome-wide Meta-analysis
13%
Induced Hypertension
13%
Induced Toxicity
13%
Inhibitor Formulations
13%
Kinase Inhibitor
13%
Meta-analysis
10%
Metabolizer
10%
Metastatic Renal Cell Carcinoma (mRCC)
85%
Odds Ratio
6%
Overall Survival
29%
PDLIM3
13%
Pediatric Cancer Patients
13%
Pediatric Oncology
22%
Pharmacogenetic Testing
13%
Pharmacogenetics
33%
Pharmacogenomics
13%
Pharmacokinetics
33%
Pharmacokinetics-pharmacodynamics (PK-PD)
15%
Population Modeling
13%
Progression-free Survival
24%
Propofol Dose
12%
Renal Cell
13%
Single nucleotide Polymorphism
37%
SU12662
16%
Sunitinib
100%
Targeted Therapy
16%
Treatment Outcome
6%
Tumor
7%
Tumor Biomarkers
13%
Tyrosine Kinase Inhibitor
22%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
13%
Adrenal Cortex Carcinoma
13%
Biological Marker
29%
Chemotherapy
16%
Childhood Cancer
17%
CYP2B6
13%
CYP3A4
19%
Cytochrome P450 3A5
17%
Cytotoxic T Lymphocyte Antigen 4
13%
Dosage Forms
13%
Event Free Survival
11%
Kidney Metastasis
68%
Malignant Neoplasm
41%
Mitotane
13%
N Deethylsunitinib
16%
Neoplasm
19%
Overall Survival
29%
Pharmacodynamics
24%
Pharmacogenetics
19%
Pharmacogenomics
13%
Pharmacokinetics
64%
Phosphotransferase Inhibitor
13%
Progression Free Survival
24%
Propofol
13%
Protein Tyrosine Kinase Inhibitor
26%
Renal Cell Carcinoma
7%
Sunitinib
99%
Vasculotropin Receptor
7%
Biochemistry, Genetics and Molecular Biology
Allele
11%
Anticancer
5%
Cancer Cell
43%
CTLA-4
13%
CYP3A4
5%
CYP3A5
17%
Down Syndrome Cell Adhesion Molecule
13%
Genetic Divergence
7%
Genetic Polymorphism
28%
Genetics
5%
Genotyping
5%
Germ Cell
7%
Germline
7%
Haplotype
5%
High Risk Population
15%
Mercaptopurine
5%
Observational Study
15%
Overall Survival
38%
Patient Coding
9%
Pharmacodynamics
8%
Pharmacogenetic Testing
13%
Pharmacogenetics
16%
Pharmacogenomics
13%
Pharmacokinetics
21%
Progression Free Survival
25%
Single-Nucleotide Polymorphism
40%
Sunitinib
89%
Tyrosine Kinase Inhibitor
21%